Xs. He et al., COSTIMULATORY PROTEIN B7-1 ENHANCES THE CYTOTOXIC T-CELL RESPONSE ANDANTIBODY-RESPONSE TO HEPATITIS-B SURFACE-ANTIGEN, Proceedings of the National Academy of Sciences of the United Statesof America, 93(14), 1996, pp. 7274-7278
There is a need for more effective therapy for chronic virus infection
s, A principle natural mechanism for elimination of virus-infected hos
t cells is activation of viral antigen-specific cytotoxic T lymphocyte
s (CTL), In an effort to develop methods of inducing virus-specific CT
L responses that might be utilized in therapy of virus infections, we
have investigated the effect of B7, a costimulatory factor for T-cell
activation, In this study we show that delivery of genes encoding huma
n B7-1 and a viral antigen in the same recombinant viral vector to cel
ls of mice induces a greater viral antigen-specific CTL response than
does similar delivery of the viral antigen gene alone, Two recombinant
adenovirus vectors were constructed with the foreign genes inserted i
n the early region 3. One of them (Ad1312) directed expression of the
surface antigen gene of hepatitis B virus (HBS); the other (Ad1310) di
rected coexpression of HBS and human B7-1 (CD80) by means of an intern
al ribosomal entry site placed between the two coding sequences, When
inoculated into BALB/c mice, both vectors induced a viral surface anti
gen-specific CTL response, The response induced by Ad1310 Ir as strong
er than that by Ad1312 as measured by a chromium release assay for CTL
activity and limiting dilution analysis for CTL precursor frequency,
indicating that the B7-1 gene co-delivered with the HBS gene had an en
hancing effect on the CTL response against surface antigen, Ad1310 als
o induced a higher titer of antibody against surface antigen than did
Ad1312. This result suggests that expression of a costimulatory protei
n and a viral antigen in the same cells in vivo induces stronger immun
e responses than expression of the antigen alone. This could be a nove
l strategy for development of both preventive and therapeutic vaccines
against infectious agents.